DDInter1425 DDInter1676
A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Pentostatin {u} (Compound) resembles {v} (Compound) Trifluridine
Pentostatin {u} (Compound) resembles {v} (Compound) Azacitidine
Pentostatin {u} (Compound) treats {v} (Disease) hematologic cancer
Pentostatin {u} (Compound) binds {v} (Gene) ADA
Pentostatin {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Pentostatin {u} (Compound) causes {v} (Side Effect) Foetor hepaticus
Pentostatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Pentostatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ofloxacin
Pentostatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Pentostatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydroxyurea
Pentostatin (Compound) resembles Trifluridine (Compound)
Pentostatin (Compound) resembles Azacitidine (Compound)
Pentostatin (Compound) treats hematologic cancer (Disease)
Pentostatin (Compound) binds ADA (Gene)
Pentostatin (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Pentostatin (Compound) causes Foetor hepaticus (Side Effect)
Pentostatin may cause a minor interaction that can limit clinical effects when taken with Enoxacin
Pentostatin may cause a minor interaction that can limit clinical effects when taken with Ofloxacin
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea